- Home
- AIHS vs RLMD Comparison
AIHS vs RLMD Comparison
Compare AIHS & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIHS
- RLMD
- Stock Information
- Founded
- AIHS 2014
- RLMD 2004
- Country
- AIHS China
- RLMD United States
- Employees
- AIHS N/A
- RLMD N/A
- Industry
- AIHS Finance: Consumer Services
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- AIHS Finance
- RLMD Health Care
- Exchange
- AIHS Nasdaq
- RLMD Nasdaq
- Market Cap
- AIHS 9.9M
- RLMD 11.5M
- IPO Year
- AIHS 2018
- RLMD N/A
- Fundamental
- Price
- AIHS $0.94
- RLMD $0.40
- Analyst Decision
- AIHS
- RLMD Hold
- Analyst Count
- AIHS 0
- RLMD 4
- Target Price
- AIHS N/A
- RLMD $4.25
- AVG Volume (30 Days)
- AIHS 22.7K
- RLMD 4.5M
- Earning Date
- AIHS 06-26-2025
- RLMD 05-12-2025
- Dividend Yield
- AIHS N/A
- RLMD N/A
- EPS Growth
- AIHS N/A
- RLMD N/A
- EPS
- AIHS N/A
- RLMD N/A
- Revenue
- AIHS $5,878,700.00
- RLMD N/A
- Revenue This Year
- AIHS N/A
- RLMD N/A
- Revenue Next Year
- AIHS N/A
- RLMD N/A
- P/E Ratio
- AIHS N/A
- RLMD N/A
- Revenue Growth
- AIHS 12.21
- RLMD N/A
- 52 Week Low
- AIHS $0.77
- RLMD $0.24
- 52 Week High
- AIHS $1.45
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- AIHS 52.38
- RLMD 51.73
- Support Level
- AIHS $0.89
- RLMD $0.36
- Resistance Level
- AIHS $1.06
- RLMD $0.44
- Average True Range (ATR)
- AIHS 0.05
- RLMD 0.08
- MACD
- AIHS 0.00
- RLMD -0.00
- Stochastic Oscillator
- AIHS 42.86
- RLMD 26.98
About AIHS Senmiao Technology Limited
Senmiao Technology Ltd is a holding company. The company's operating segment includes Automobile Transaction and Related Services focusing on the online ride-hailing industry in the People's Republic of China and Online ride-hailing platform Services through its own platform, Xixingtianxia. It generates maximum revenue from the Automobile Transaction and Related Services segment. Geographically, it derives revenue from China.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.